The following statement was issued by David Mitchell, a cancer patient and founder and president of Patients For Affordable Drugs, in response to the pricing of Relyvrio following the Food and Drug Administration’s approval of the drug combination to treat amyotrophic lateral sclerosis (ALS):
Basey Has Devoted Her Career To Ensuring That Life-saving Medications Are Affordable And Accessible For All Who Need Them
In The Third Year Of The Pandemic And As Americans Grapple With Record Inflation, Big Pharma Continues To Raise Prices And Exploit Patients
A new report issued today documents how drug companies use their market and political power to avoid competition and raise prices in lockstep.
Since P4AD’s initial report in mid-January, drug companies have increased the price of 188 more drugs, bringing the total to 742 hikes so far this year.
The report demonstrates why urgent congressional action is needed to address Big Pharma’s abusive pricing practices.
"Patients are counting on Congress and the Biden administration to deliver drug pricing reforms immediately in this new year."
The Build Back Better Act “Will Make Our System Work Better For Those It Is Intended To Serve: Patients And All Americans”
Patients For Affordable Drugs is the only independent national patient organization focused exclusively on achieving policy changes to lower the price of prescription drugs.
